Literature DB >> 12636171

Sterically stabilized phospholipid mixed micelles: in vitro evaluation as a novel carrier for water-insoluble drugs.

Aparna Krishnadas1, Israel Rubinstein, Hayat Onyüksel.   

Abstract

PURPOSE: Sterically stabilized phospholipid micelles (SSMs) composed of poly(ethylene glycol-2000)-grafted distearoyl phosphatidylethanolamine (PEG(2000)-DSPE) are new and promising lipid-based carriers for water-insoluble drugs. This study investigates and compares sterically stabilized mixed micelles (SSMM), composed of (PEG(2000)-DSPE) plus egg-phosphatidylcholine, with SSM as a novel delivery system for improved solubilization of water-insoluble drugs using paclitaxel as a model.
METHODS: Paclitaxel was solubilized in SSM (P-SSM) and SSMM (P-SSMM) by coprecipitation and rehydration with isotonic 0.01M HEPES buffer, pH 7.4. After separation of excess drug by centrifugation, mean particle size and morphology of particles in the supernatant were determined by quasi-elastic light scattering and transmission electron microscopy. The solubilization potentials of SSMM and SSM for paclitaxel were determined by reverse phase high pressure liquid chromatography (RP-HPLC). Cytotoxic activity of paclitaxel in SSMM. SSM, and dimethyl sulfoxide (10% DMSO) was determined against human breast cancer cells (MCF-7).
RESULTS: Mean hydrodynamic diameter of P-SSMM and P-SSM were 13.1 +/- 1.1 nm and 15 +/- 1 nm (n = 3), respectively. SSMM solubilized 1.5 times more paclitaxel than SSM for the same total lipid concentration. Solubilized paclitaxel amount increased linearly with an increase in lipid concentration. A therapeutically relevant lipid concentration (15 mM) of SSMM solubilized 1,321 +/- 48 microg/ml of paclitaxel. Paclitaxel in the absence of sufficient SSM aggregated to form lipid-coated crystals. P-SSMM, P-SSM. and paclitaxel in DMSO had comparable cytotoxic activities against MCF-7 cells.
CONCLUSIONS: SSMM showed increased solubilization potential compared with SSM while retaining all of its own advantages. Therefore, it can be used as an improved lipid-based carrier for water-insoluble drugs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12636171     DOI: 10.1023/a:1022243709003

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  17 in total

1.  A systematic SAR study of C10 modified paclitaxel analogues using a combinatorial approach.

Authors:  Yanbin Liu; Syed M Ali; Thomas C Boge; Gunda I Georg; Samuel Victory; Jan Zygmunt; Rebecca T Marquez; Richard H Himes
Journal:  Comb Chem High Throughput Screen       Date:  2002-02       Impact factor: 1.339

2.  A multistep model for paclitaxel-induced apoptosis in human breast cancer cell lines.

Authors:  A L Blajeski; T J Kottke; S H Kaufmann
Journal:  Exp Cell Res       Date:  2001-11-01       Impact factor: 3.905

Review 3.  Structure and design of polymeric surfactant-based drug delivery systems.

Authors:  V P Torchilin
Journal:  J Control Release       Date:  2001-06-15       Impact factor: 9.776

4.  Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles.

Authors:  L van Zuylen; M O Karlsson; J Verweij; E Brouwer; P de Bruijn; K Nooter; G Stoter; A Sparreboom
Journal:  Cancer Chemother Pharmacol       Date:  2001-04       Impact factor: 3.333

5.  Experimental and Monte Carlo simulation studies of the thermodynamics of polyethyleneglycol chains grafted to lipid bilayers.

Authors:  S Rex; M J Zuckermann; M Lafleur; J R Silvius
Journal:  Biophys J       Date:  1998-12       Impact factor: 4.033

6.  Accumulation of protein-loaded long-circulating micelles and liposomes in subcutaneous Lewis lung carcinoma in mice.

Authors:  V Weissig; K R Whiteman; V P Torchilin
Journal:  Pharm Res       Date:  1998-10       Impact factor: 4.200

7.  Novel taxol formulations: preparation and characterization of taxol-containing liposomes.

Authors:  A Sharma; R M Straubinger
Journal:  Pharm Res       Date:  1994-06       Impact factor: 4.200

8.  A novel formulation of VIP in sterically stabilized micelles amplifies vasodilation in vivo.

Authors:  H Onyüksel; H Ikezaki; M Patel; X P Gao; I Rubinstein
Journal:  Pharm Res       Date:  1999-01       Impact factor: 4.200

9.  Mixed micelles as proliposomes for the solubilization of teniposide.

Authors:  H Alkan-Onyuksel; K Son
Journal:  Pharm Res       Date:  1992-12       Impact factor: 4.200

Review 10.  Paclitaxel (taxol).

Authors:  D R Kohler; B R Goldspiel
Journal:  Pharmacotherapy       Date:  1994 Jan-Feb       Impact factor: 4.705

View more
  41 in total

1.  Intracellular delivery of VIP-grafted sterically stabilized phospholipid mixed nanomicelles in human breast cancer cells.

Authors:  Israel Rubinstein; Imre Soos; Hayat Onyuksel
Journal:  Chem Biol Interact       Date:  2007-04-06       Impact factor: 5.192

2.  VIP-grafted sterically stabilized phospholipid nanomicellar 17-allylamino-17-demethoxy geldanamycin: a novel targeted nanomedicine for breast cancer.

Authors:  Hayat Onyüksel; Prem S Mohanty; Israel Rubinstein
Journal:  Int J Pharm       Date:  2008-08-27       Impact factor: 5.875

3.  Preclinical development of drug delivery systems for paclitaxel-based cancer chemotherapy.

Authors:  Feihu Wang; Michael Porter; Alexandros Konstantopoulos; Pengcheng Zhang; Honggang Cui
Journal:  J Control Release       Date:  2017-09-25       Impact factor: 9.776

4.  Lipid Shell Composition Plays a Critical Role in the Stable Size Reduction of Perfluorocarbon Nanodroplets.

Authors:  Steven K Yarmoska; Heechul Yoon; Stanislav Y Emelianov
Journal:  Ultrasound Med Biol       Date:  2019-04-08       Impact factor: 2.998

Review 5.  A review of solute encapsulating nanoparticles used as delivery systems with emphasis on branched amphipathic peptide capsules.

Authors:  Sheila M Barros; Susan K Whitaker; Pinakin Sukthankar; L Adriana Avila; Sushanth Gudlur; Matt Warner; Eduardo I C Beltrão; John M Tomich
Journal:  Arch Biochem Biophys       Date:  2016-02-27       Impact factor: 4.013

6.  Solubilization of therapeutic agents in micellar nanomedicines.

Authors:  Lela Vuković; Antonett Madriaga; Antonina Kuzmis; Amrita Banerjee; Alan Tang; Kevin Tao; Neil Shah; Petr Král; Hayat Onyuksel
Journal:  Langmuir       Date:  2013-12-09       Impact factor: 3.882

7.  Self-associated indisulam in phospholipid-based nanomicelles: a potential nanomedicine for cancer.

Authors:  Hacer Cesur; Israel Rubinstein; Ashwini Pai; Hayat Onyüksel
Journal:  Nanomedicine       Date:  2008-12-13       Impact factor: 5.307

8.  Enhanced cytotoxicity of TATp-bearing paclitaxel-loaded micelles in vitro and in vivo.

Authors:  Rupa R Sawant; Vladimir P Torchilin
Journal:  Int J Pharm       Date:  2009-03-27       Impact factor: 5.875

9.  Curcumin in VIP-targeted sterically stabilized phospholipid nanomicelles: a novel therapeutic approach for breast cancer and breast cancer stem cells.

Authors:  Ece Gülçür; Mentor Thaqi; Fatima Khaja; Antonina Kuzmis; Hayat Önyüksel
Journal:  Drug Deliv Transl Res       Date:  2013-12       Impact factor: 4.617

10.  VIP-targeted Cytotoxic Nanomedicine for Breast Cancer.

Authors:  Aparna Dagar; Antonina Kuzmis; Israel Rubinstein; Marin Sekosan; Hayat Onyuksel
Journal:  Drug Deliv Transl Res       Date:  2012-12-01       Impact factor: 4.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.